NIAID launches major step in trial of experimental shingles vaccine

June 15, 1999

On June 17, researchers at NIAID will launch an important next step in a study of an experimental vaccine to prevent shingles (also known as herpes zoster, or just "zoster"). In the so-called Phase III trial, the team will study the vaccine's safety and how well it works to prevent the disease.

Dr. Philip Brunell, an internationally renowned pediatrician and expert on the chickenpox virus, will officially open the trial by rolling up his sleeve to become the first person to be immunized with the experimental vaccine. The NIAID study will test a more potent version of the vaccine used to immunize children against the chickenpox virus. Earlier studies have shown the study vaccine to be safe and well tolerated.

At 68, Dr. Brunell believes strongly in the new vaccine's potential. "After almost 40 years of studying varicella-zoster virus," he said, "it is exciting for me to now be involved in testing this vaccine. Zoster, or shingles, is a very significant concern for those of us over 60, as the chance of getting it increases and the condition is often more severe as we grow older."

Shingles is a major health problem in older adults. Any individual has a 20 percent chance of developing it during his or her lifetime. Of the hundreds of thousands of people in the United States who will be diagnosed with shingles this year, most will be over age 60.

Shingles is caused by the same virus, varicella-zoster (VZV), that causes chickenpox. After a person has had chickenpox, VZV remains in the nerve cells by the spinal cord for life but is usually dormant. If it becomes reactivated, however, it can cause shingles. Early symptoms may include an outbreak of rash or blisters - usually on one side of the body or face - burning, tingling or shooting pain. Although skin symptoms may heal within weeks, the pain (called post-herpetic neuralgia) can be intense, severely debilitating and last for years. Other serious complications, such as blindness or hearing loss, may also occur.

As people who have had chickenpox age, their body's ability to suppress the virus is compromised, making them more susceptible to shingles. Once they have had shingles, they seldom have a recurrence, suggesting that the episode boosts immunity which then keeps the virus in check.

"We believe that by boosting the body's immune response with this vaccine - mimicking a naturally occurring case of zoster - shingles and post-herpetic neuralgia may be prevented," said Norberto Emilio Soto, M.D., principal investigator on the study.

The national trial of approximately 20 medical centers is recruiting a total of 37,000 volunteers - 1,800 in the metropolitan Washington, D.C., area - and is funded by the Veterans Administration, Merck & Co., and NIAID.

Volunteers Needed

People are invited to participate in this medical research study if they:
Those interested in participating or obtaining more information should call 1-800-411-1222. Extra copies of flyers for recruiting study participants, and fact sheets on shingles and the shingles prevention study, may be obtained by calling 1-800-772-5464 ext. 658. Media interested in attending the event on June 17 at the NIH Clinical Center should call the NIAID press office to make arrangements.
-end-
NIAID and the Clinical Center are components of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. The Clinical Center conducts clinical research on a wide variety of conditions including cancer, AIDS, mental illness and rare diseases. NIH is an agency of the U.S. Department of Health and Human Services. Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related Immune Response Articles from Brightsurf:

Boosting chickens' own immune response could curb disease
Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

Cells sacrifice themselves to boost immune response to viruses
Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Children's immune response more effective against COVID-19
Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept.

Which immune response could cause a vaccine against COVID-19?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

Obesity may alter immune system response to COVID-19
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

Immune response to Sars-Cov-2 following organ transplantation
Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2.

'Relaxed' T cells critical to immune response
Rice University researchers model the role of relaxation time as T cells bind to invaders or imposters, and how their ability to differentiate between the two triggers the body's immune system.

A novel mechanism that triggers a cellular immune response
Researchers at Baylor College of Medicine present comprehensive evidence that supports a novel trigger for a cell-mediated response and propose a mechanism for its action.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

How to boost immune response to vaccines in older people
Identifying interventions that improve vaccine efficacy in older persons is vital to deliver healthy ageing for an ageing population.

Read More: Immune Response News and Immune Response Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.